Research Study

A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma
Principal Investigator 
Heather J. Sutherland

Overview

Disorders and Conditions 
Multiple Myeloma
ClinicalTrials.gov# 
NCT03277105
Status 
Recruiting
Study Start/End 
Feb 1, 2018 to Nov 5, 2019
Locations 
Vancouver General Hospital
Name/Title 
Phenicia Azurin, Research Assistant
Phone 
604-875-4111 ext.22960
Purpose of Study 

The purpose of this study is to show that subcutaneous (SC) administration of daratumumab co-formulated with recombinant human hyaluronidase PH20 (Dara SC) is non-inferior to intravenous (IV) administration of daratumumab (Dara IV) in terms of the overall response rate (ORR) and maximum trough concentration (Ctrough).

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.